Does the media favor ARDX or ENTA?

In the previous week, Ardelyx had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 4 mentions for Ardelyx and 3 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.73 beat Ardelyx's score of 0.62 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GHRS or ENTA?

In the previous week, GH Research had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 4 mentions for GH Research and 3 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.73 beat GH Research's score of 0.47 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer INBX or ENTA?

In the previous week, Inhibrx Biosciences and Inhibrx Biosciences both had 3 articles in the media. Enanta Pharmaceuticals' average media sentiment score of 0.73 beat Inhibrx Biosciences' score of 0.51 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MAZE or ENTA?

In the previous week, Maze Therapeutics had 4 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 7 mentions for Maze Therapeutics and 3 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.73 beat Maze Therapeutics' score of 0.21 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Enanta Pharmaceuticals (ENTA) Competitors

$14.30 +0.30 (+2.11%)

As of 11:30 AM Eastern

Compare

ENTA vs. ARDX, MLTX, GHRS, INBX, and MAZE

Should you buy Enanta Pharmaceuticals stock or one of its competitors? MarketBeat compares Enanta Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enanta Pharmaceuticals include Ardelyx (ARDX), MoonLake Immunotherapeutics (MLTX), GH Research (GHRS), Inhibrx Biosciences (INBX), and Maze Therapeutics (MAZE). These companies are all part of the "pharmaceutical products" industry.

How does Enanta Pharmaceuticals compare to Ardelyx?

Ardelyx (NASDAQ:ARDX) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Ardelyx has a net margin of -13.58% compared to Enanta Pharmaceuticals' net margin of -89.56%. Ardelyx's return on equity of -38.11% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

In the previous week, Ardelyx had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 4 mentions for Ardelyx and 3 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.73 beat Ardelyx's score of 0.62 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ardelyx has higher revenue and earnings than Enanta Pharmaceuticals. Ardelyx is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$427.68M	3.07	-$61.60M	-$0.23	N/A
Enanta Pharmaceuticals	$65.32M	6.32	-$81.89M	-$2.59	N/A

58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Ardelyx has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

Ardelyx currently has a consensus target price of $15.73, indicating a potential upside of 195.90%. Enanta Pharmaceuticals has a consensus target price of $20.29, indicating a potential upside of 42.96%. Given Ardelyx's stronger consensus rating and higher probable upside, equities research analysts plainly believe Ardelyx is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Ardelyx beats Enanta Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

In the previous week, MoonLake Immunotherapeutics had 13 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 16 mentions for MoonLake Immunotherapeutics and 3 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.73 beat MoonLake Immunotherapeutics' score of 0.57 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	4 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Enanta Pharmaceuticals' return on equity of -64.04% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

MoonLake Immunotherapeutics presently has a consensus price target of $23.85, suggesting a potential upside of 19.72%. Enanta Pharmaceuticals has a consensus price target of $20.29, suggesting a potential upside of 42.96%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 12.1% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Enanta Pharmaceuticals has higher revenue and earnings than MoonLake Immunotherapeutics. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Enanta Pharmaceuticals	$65.32M	6.32	-$81.89M	-$2.59	N/A

MoonLake Immunotherapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Summary

Enanta Pharmaceuticals beats MoonLake Immunotherapeutics on 9 of the 15 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to GH Research?

GH Research (NASDAQ:GHRS) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

GH Research has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. GH Research's return on equity of -19.36% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

GH Research has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

56.9% of GH Research shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

GH Research has higher earnings, but lower revenue than Enanta Pharmaceuticals. GH Research is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
Enanta Pharmaceuticals	$65.32M	6.32	-$81.89M	-$2.59	N/A

GH Research currently has a consensus price target of $40.38, indicating a potential upside of 43.81%. Enanta Pharmaceuticals has a consensus price target of $20.29, indicating a potential upside of 42.96%. Given GH Research's higher probable upside, equities analysts plainly believe GH Research is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, GH Research had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 4 mentions for GH Research and 3 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.73 beat GH Research's score of 0.47 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

GH Research beats Enanta Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Inhibrx Biosciences has a beta of 3.33, indicating that its stock price is 233% more volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Enanta Pharmaceuticals has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,046.31	-$140.05M	-$8.39	N/A
Enanta Pharmaceuticals	$65.32M	6.32	-$81.89M	-$2.59	N/A

Inhibrx Biosciences has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Enanta Pharmaceuticals' return on equity of -64.04% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

In the previous week, Inhibrx Biosciences and Inhibrx Biosciences both had 3 articles in the media. Enanta Pharmaceuticals' average media sentiment score of 0.73 beat Inhibrx Biosciences' score of 0.51 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibrx Biosciences currently has a consensus price target of $150.00, indicating a potential upside of 61.78%. Enanta Pharmaceuticals has a consensus price target of $20.29, indicating a potential upside of 42.96%. Given Inhibrx Biosciences' higher possible upside, equities research analysts plainly believe Inhibrx Biosciences is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Enanta Pharmaceuticals beats Inhibrx Biosciences on 10 of the 16 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Maze Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Maze Therapeutics' return on equity of -36.62% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.62%	-31.78%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

Maze Therapeutics has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Maze Therapeutics currently has a consensus price target of $66.00, indicating a potential upside of 134.28%. Enanta Pharmaceuticals has a consensus price target of $20.29, indicating a potential upside of 42.96%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Maze Therapeutics is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Enanta Pharmaceuticals has lower revenue, but higher earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	9.31	-$131.12M	-$2.53	N/A
Enanta Pharmaceuticals	$65.32M	6.32	-$81.89M	-$2.59	N/A

In the previous week, Maze Therapeutics had 4 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 7 mentions for Maze Therapeutics and 3 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.73 beat Maze Therapeutics' score of 0.21 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Maze Therapeutics beats Enanta Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Enanta Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTA vs. The Competition

Export

Metric	Enanta Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$412.70M	$3.05B	$6.85B	$12.33B
Dividend Yield	N/A	1.87%	2.67%	6.11%
P/E Ratio	-5.48	19.58	25.86	24.20
Price / Sales	6.32	339.52	550.66	101.54
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	4.68	4.22	10.89	6.42
Net Income	-$81.89M	$64.45M	$3.58B	$336.87M
7 Day Performance	6.13%	3.39%	2.51%	0.94%
1 Month Performance	7.83%	0.65%	0.22%	-0.53%
1 Year Performance	89.20%	31.70%	35.34%	27.96%

Enanta Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTA Enanta Pharmaceuticals	1.9482 of 5 stars	$14.30 +2.1%	$20.29 +41.9%	+86.7%	$415.70M	$65.32M	N/A	160
ARDX Ardelyx	2.6019 of 5 stars	$5.67 -0.2%	$15.73 +177.4%	+50.0%	$1.40B	$407.32M	N/A	90
MLTX MoonLake Immunotherapeutics	2.711 of 5 stars	$18.98 -1.1%	$23.85 +25.6%	-58.1%	$1.40B	N/A	N/A	2
GHRS GH Research	3.4632 of 5 stars	$19.98 -1.9%	$40.38 +102.1%	+126.8%	$1.37B	N/A	N/A	10	News Coverage
INBX Inhibrx Biosciences	2.4808 of 5 stars	$93.11 -0.4%	$150.00 +61.1%	+557.0%	$1.37B	$1.30M	N/A	166	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTA) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. ARDX, MLTX, GHRS, INBX, and MAZE

How does Enanta Pharmaceuticals compare to Ardelyx?

Summary

How does Enanta Pharmaceuticals compare to MoonLake Immunotherapeutics?

Summary

How does Enanta Pharmaceuticals compare to GH Research?

Summary

How does Enanta Pharmaceuticals compare to Inhibrx Biosciences?

Summary

How does Enanta Pharmaceuticals compare to Maze Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. ARDX, MLTX, GHRS, INBX, and MAZE

How does Enanta Pharmaceuticals compare to Ardelyx?

Is ARDX or ENTA more profitable?

Does the media favor ARDX or ENTA?

Which has higher earnings and valuation, ARDX or ENTA?

Do insiders & institutionals believe in ARDX or ENTA?

Which has more risk & volatility, ARDX or ENTA?

Do analysts prefer ARDX or ENTA?

Summary

How does Enanta Pharmaceuticals compare to MoonLake Immunotherapeutics?

Does the media refer more to MLTX or ENTA?

Is MLTX or ENTA more profitable?

Do analysts rate MLTX or ENTA?

Do institutionals and insiders hold more shares of MLTX or ENTA?

Which has better earnings & valuation, MLTX or ENTA?

Which has more volatility & risk, MLTX or ENTA?

Summary

How does Enanta Pharmaceuticals compare to GH Research?

Is GHRS or ENTA more profitable?

Which has more volatility and risk, GHRS or ENTA?

Do institutionals and insiders have more ownership in GHRS or ENTA?

Which has stronger valuation and earnings, GHRS or ENTA?

Do analysts prefer GHRS or ENTA?

Does the media favor GHRS or ENTA?

Summary

How does Enanta Pharmaceuticals compare to Inhibrx Biosciences?

Do institutionals and insiders hold more shares of INBX or ENTA?

Which has more risk and volatility, INBX or ENTA?

Which has better valuation & earnings, INBX or ENTA?

Is INBX or ENTA more profitable?

Does the media prefer INBX or ENTA?

Do analysts rate INBX or ENTA?

Summary

How does Enanta Pharmaceuticals compare to Maze Therapeutics?

Is MAZE or ENTA more profitable?

Which has more risk & volatility, MAZE or ENTA?

Do analysts recommend MAZE or ENTA?

Which has stronger earnings and valuation, MAZE or ENTA?

Does the media prefer MAZE or ENTA?

Do institutionals & insiders believe in MAZE or ENTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools